Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 3/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21996407 | 0.83 | FDPS (0.38) | FDPSTSHRARCYP3A4NOS1 | |
| SCHEMBL309198 | 0.82 | FDPS (0.38) | FDPSTSHRARCYP3A4NOS1 | |
| SCHEMBL14451165 | 0.82 | FDPS (0.38) | FDPSTSHRARCYP3A4NOS1 | |
| SCHEMBL31030327 | 0.82 | FDPS (0.37) | FDPSTSHRARCYP3A4NOS1 | |
| SCHEMBL29699401 | 0.81 | FDPS (0.39) | FDPSTSHRARCYP3A4NOS1 | |
| SCHEMBL17616429 | 0.80 | FDPS (0.40) | FDPSTSHRARCYP3A4NOS1 | |
| SCHEMBL30630104 | 0.79 | FFAR1 (0.35) | FFAR1 | |
| SCHEMBL21996409 | 0.79 | FDPS (0.38) | FDPSTSHRNOS1NOS3HDAC1 | |
| SCHEMBL31030353 | 0.79 | FDPS (0.35) | FDPSTSHRARCYP3A4NOS1 | |
| SCHEMBL11971015 | 0.79 | AR (0.36) | FDPSTSHRARCYP3A4NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110036004-A | Inhibitors of cyclin dependent kinase 7(CDK7) | 希洛斯医药品股份有限公司 | 2019-07-19 | — | — | CN | claimed |
| WO-2016041618-A1 | SUBSTITUTED INDAZOLES AND RELATED HETEROCYCLES | MERCK PATENT GMBH (DE) | 2016-03-24 | — | — | WO | claimed |
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-02-19 | — | — | US | disclosed |
| US-12448379-B2 | Wild type kit inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-12263171-B2 | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2025-04-01 | — | — | US | disclosed |
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240262826-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-08-08 | — | — | US | disclosed |
| US-20240246946-A1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-20240139163-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2024-05-02 | — | — | US | disclosed |
| WO-2020135878-A1 | IMIDAZOPYRIDINE DERIVATIVE AS FGFR AND VEGFR DUAL INHIBITOR | 南京明德新药研发有限公司 | 2020-07-02 | — | — | WO | disclosed |
| WO-2020112700-A1 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-9597310-B2 | Indanyloxydihydrobenzofuranylacetic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| WO-2016041618-A1 | SUBSTITUTED INDAZOLES AND RELATED HETEROCYCLES | MERCK PATENT GMBH (DE) | 2016-03-24 | — | — | WO | disclosed |
| WO-2014086712-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-12 | — | — | WO | disclosed |
| US-8716482-B2 | Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2480082-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | Merck Sharp & Dohme Corp. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
| WO-2011037793-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | FDPS 4751/4885TSHR 2892/4885AR 858/4885 |
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | KIT, CSNK1A1, CSNK1A1L | FDPS 4691/4885TSHR 3143/4885AR 2481/4885 |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | FDPS 4751/4885TSHR 2892/4885AR 858/4885 |
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | FDPS 3845/4885TSHR 131/4885AR 519/4885 |
| US-12448379-B2 | Wild type kit inhibitors | KIT, TNK1, TNNI3K | FDPS 4159/4885TSHR 4256/4885AR 4179/4885 |
| US-20240246946-A1 | MODULATORS OF TREX1 | CFTR, SLC10A1, CYP27A1 | FDPS 815/4885TSHR 1272/4885AR 3818/4885 |
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | FDPS 421/4885TSHR 3776/4885AR 3870/4885 |
| US-20240262826-A1 | WILD TYPE KIT INHIBITORS | KIT, TNK1, TNNI3K | FDPS 4159/4885TSHR 4256/4885AR 4179/4885 |
| US-12263171-B2 | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | FDPS 4393/4885TSHR 136/4885AR 505/4885 |
| US-20240139163-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | FDPS 4751/4885TSHR 2892/4885AR 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.